Effect of Augmentation Cystoplasty on Bone Metabolism in Chronic Uremic Rats

Brkovic, D.; Seibel, Markus J.; Juchem, Rolf; Linke, Joachim; Rohde, D.; Bauss, Frieder

doi:10.1097/01.ju.0000104561.90514.cb

Cited by 10 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, augmented animals, which developed metabolic acidosis, had shorter femur lengths than controls and whole body BMD was decreased. Brkovic et al [21] reported the DEXA results of uremic rats, which underwent augmentation cystoplasty with stomach, ileum, and sigmoid colon. Mean BMD values of augmented rats were lower than the control group, even though pH values of each group were within the physiological range.…”

Section: Discussionmentioning

confidence: 98%

“…Although almost all the clinical and experimental studies [18,19,[21][22][23] did the bone density measurement at the spine, we also included femoral neck BMD measurements to compare the neurogenic and non-neurogenic groups. The femoral neck BMD decreased 28% in neurogenic group and 13.8% in non-neurogenic group, when compared to age-and sex-matched population [24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of bone mineral density after ileocystoplasty in children with and without myelomeningocele

et al. 2006

View full text Add to dashboard Cite

We evaluated the bone mineral density (BMD) after ileal augmentation cystoplasty in a group of children with and without myelomeningocele. Between 1996 and 2003, eight patients with neurogenic bladder and seven patients with non-neurogenic bladder underwent augmentation ileocystoplasty. Preoperative and postoperative serum creatinine and electrolytes were measured. All patients underwent clinical evaluation, supine height measurement, blood gas analysis, and BMD measurement using a dual energy X-ray absorptiometry (DEXA) postoperatively. BMD was measured at L1-L4 and femoral neck, and compared to age- and sex-matched population. Follow-up time was calculated from the day of surgery to the day of DEXA performance. A total of eight boys and seven girls with the mean age of 10.2 +/- 4.1 years were evaluated with respect to BMD measurement. Mean age was 9.8 years in neurogenic group and 10.5 in non-neurogenic group. Mean follow-up was 728 and 616 days in neurogenic and non-neurogenic groups, respectively. There were no significant differences between ages, follow-up times, preoperative and postoperative creatinine levels, pH and bicarbonate values, and supine heights. Mean BMD at L1-L4 was 55.7% in neurogenic group and 83.8% in non-neurogenic group. There was a statistically significant difference between the two groups (P = 0.02). Mean BMD at femoral neck was 72% in neurogenic group and 86.2% in non-neurogenic group. The difference was also statistically significant (P = 0.028). After augmentation ileocystoplasty, the BMD in early postoperative period of patients with myelomeningocele is lower than the patients with non-neurogenic neurogenic bladder, which have the same clinical characteristics except the neurologic pathology. In the light of our findings and the reported literature data as well, we may claim that BMD decrease after augmentation ileocystoplasty depends more on the underlying neurologic pathology and its locomotor consequences rather than the enterocystoplasty itself.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Evaluation of bone mineral density after ileocystoplasty in children with and without myelomeningocele

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Animals were randomly allocated to receive weekly subcutaneous injections of either vehicle (0.9% saline) or ibandronate (Bondronate; Roche Diagnostics, Mannheim, Germany; 1.25 μg/kg body weight) for a total of 10 weeks. This dosage was selected since it was shown to be well tolerated in uremic rats and can be given once weekly [17,20,21]. Four groups were included in the study: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated CRF rats; (4) ibandronate-treated CRF rats.…”

Section: Animals and Experimental Protocolmentioning

confidence: 99%

Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function

et al. 2010

View full text Add to dashboard Cite

Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injections of either vehicle or ibandronate (1.25 μg/kg body weight) for a total of 10 weeks. The rats were randomly allocated into one of four groups: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated, 5/6 nephrectomized rats; (4) ibandronate-treated, 5/6 nephrectomized rats. Bones were double labeled with tetracycline and demeclocycline in vivo, and tibiae were removed for analysis. Weight gain was similar in all groups. Ibandronate reduced body length gain and tibial growth rate in the sham-operated animals but not in the rats showing chronic renal failure (CRF). The height of the proliferative zone of the epiphyseal growth plate was reduced in the ibandronate-treated controls and tended to be reduced in CRF rats. A significant correlation between tibial growth rate and height of the proliferative zone was observed. Mineral apposition rates were significantly reduced in ibandronate-treated, sham-operated rats and tended to be reduced in CRF rats. In conclusion, ibandronate interferes with tibial growth and bone mineralization in young rats with normal and reduced renal function.

show abstract

“…The impact of urinary diversion using several types of intestinal segments on the bone metabolism of growing rats with renal insufficiency was examined by Brkovic et al [30]. Uremic rats underwent enterocystoplasty using stomach, ileum, or colon.…”

Section: Preclinical Evidence For Differing Renal Safety Profilesmentioning

confidence: 99%

Preclinical Perspectives on Bisphosphonate Renal Safety

2005

Self Cite

View full text Add to dashboard Cite

Renal insufficiency is not rare in cancer patients who may receive nephrotoxic medications as antineo-plastic agents or for comorbid conditions. Thus, the choice of a particular bisphosphonate for patients with metastatic bone disease should be based not only on efficacy but also on the risk for renal deterioration. Some i.v. bisphosphonates have been associated with occasional renal toxicity in the clinical setting. Preclinical studies have also shown that there may be considerable differences among bisphosphonate renal safety profiles. Comparative studies show variations in the risk for histopathologic damage and the ability to cause cumulative toxicity during intermittent dosing. Reasons for the differences among bisphosphonates are not fully understood; however, research shows that they may be influenced by pharmacokinetic properties such as renal tissue half-life or protein binding and intracellular potency. Further preclinical analyses are needed to confirm and evaluate differences among bisphosphonates.

show abstract

Effect of Augmentation Cystoplasty on Bone Metabolism in Chronic Uremic Rats

Abstract: Our results suggest that cystoplasty using ileum segments can aggravate renal bone disease in growing rats with mild uremia. Since the acid-base state was unchanged, other properties of the interposed ileum segment must be responsible for the negative effect on bone metabolism.

Cited by 10 publications

References 16 publications

Evaluation of bone mineral density after ileocystoplasty in children with and without myelomeningocele

Evaluation of bone mineral density after ileocystoplasty in children with and without myelomeningocele

Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function

Preclinical Perspectives on Bisphosphonate Renal Safety

Contact Info

Product

Resources

About